Skip to search formSkip to main contentSkip to account menu

ado-trastuzumab emtansine 160 MG Injection [KADCYLA]

Known as: ADO-TRASTUZUMAB EMTANSINE 20 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [KADCYLA], KADCYLA 160 MG Injection 
National Institutes of Health

Related topics

Related topics

8 relations
InjectionKADCYLAPolysorbate 20Sodium Hydroxide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
ADCs on the Market and in Clinical Development
Antibody–drug conjugates (ADCs) represent a promising class of drugs with a wider therapeutic index (TI) than conventional… 
2017
2017
Enzyme-Based Strategies to Generate Site-Specifically Conjugated Antibody Drug Conjugates
Antibody Drug Conjugates (ADCs) exploit the specificity of monoclonal antibodies for the targeting of highly potent small… 
2017
2017
A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) are complex drug platforms composed of monoclonal antibodies (mAbs) conjugated to potent… 
Review
2016
Review
2016
Antibody–drug conjugates for targeted anticancer drug delivery
Antibody–drug conjugates (ADCs) are tumor-targeted therapeutic agents that combine the specificity of monoclonal antibodies (mAbs… 
2015
2015
Abstract 5360: The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers
SYD985 is a HER2-targeting ADC based on trastuzumab and vc-seco-DUBA, Synthon9s proprietary cleavable linker-duocarmycin payload… 
Review
2015
Review
2015
Pertuzumab et T-DM1 : de nouvelles perspectives dans le traitement du cancer du sein HER2 positif
RésuméLe trastuzumab (Herceptine®, Roche) a complètement révolutionné le pronostic du cancer du sein HER2 positif, que ce soit en… 
2015
2015
Употреба на Herceptin® (трастузумаб) и неговиот конјугат Kadcyla® (трастузумаб-емтанзин) во терапија на рак на дојка
Трастузумабот е првото одобрено хуманизирано моноклонално антитело, кое е активно против HER2/neu позитивен рак на дојка. HER2… 
2015
2015
Abstract 3601: Antibody-drug conjugates (ADCs) with tubulysin and PBD warheads, maintain potent in vitro cytotoxicity against multidrug-resistant tumor cells expressing P-glycoprotein (P-gp)
Development of resistance to initially-effective therapies remains a major challenge in the treatment of cancer. Resistance to… 
2014
2014
Human antibody phage technology - isolation and characterization of monoclonal antibodies for the targeting of cancer and rheumatoid arthritis
Review
2013
Review
2013
Trastuzumab emtansine (Kadcyla™) for previously treated patients with HER2-positive advanced/metastatic breast cancer
Trastuzumab emtansine (T-DM1) is currently not yet licensed in Europe, but has received market authorisation in the U.S. based on… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)